• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by SenesTech Inc.

    5/7/26 4:19:20 PM ET
    $SNES
    Agricultural Chemicals
    Industrials
    Get the next $SNES alert in real time by email
    DEFA14A 1 snes-20260507xdefa14a.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    _________________
    SCHEDULE 14A
    (Rule 14a 101)
    _________________
    INFORMATION REQUIRED IN PROXY STATEMENT
    SCHEDULED 14A INFORMATION
    Proxy Statement Pursuant to Section 14(a)
    of the Securities Exchange Act of 1934
    (Amendment No. __)
    Filed by the Registrant☒
    Filed by a Party other than the Registrant☐
    Check the appropriate box:
    ☐Preliminary Proxy Statement
    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐Definitive Proxy Statement
    ☒Definitive Additional Materials
    ☐Soliciting Material Pursuant to §240.14a-12
    SenesTech, Inc.
    (Name of Registrant as Specified in its Charter)
    _______________________________________________________________
    (Name of Person(s) Filing Proxy Statement if other than the Registrant)
    Payment of Filing Fee (Check in the appropriate box):
    ☒No fee required.
    ☐Fee paid previously with preliminary materials.
    ☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11.



    SENESTECH, INC.
    Supplement to Proxy Statement
    For Annual Meeting of Stockholders
    To be held on June 9, 2026

    EXPLANATORY NOTE
    The following (collectively, the “Supplemental Disclosure”) supplements the disclosures set forth in the Company’s definitive proxy statement (the “Proxy Statement”), as filed with the U.S. Securities and Exchange Commission on April 29, 2026, under the headings:
    •“Proposal One – Election of Directors - Nominees and Continuing Directors”, “Continuing Directors” and “Executive Officers”,
    •“Corporate Governance”,
    •“Executive Compensation – Employment Agreements”, and
    •“Proposal Three – Approval of an Amendment to the 2018 Equity Incentive Plan – New Plan Benefits”
    The Supplemental Disclosure does not change the proposals to be acted on at the Annual Meeting or the recommendation of the Board with respect to any proposals. Except as specifically supplemented by the information contained in the Supplemental Disclosure, all information set forth in the Proxy Statement continues to apply and should be considered in voting your shares. Capitalized terms used in this Supplemental Disclosure and not otherwise defined herein have the meaning given to them in the Proxy Statement.

    THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.
    EXCEPT AS SPECIFICALLY SUPPLEMENTED BY THE INFORMATION CONTAINED HEREIN, THIS SUPPLEMENT DOES NOT MODIFY ANY OTHER INFORMATION SET FORTH IN THE PROXY STATEMENT.



    Appointment of Michael Edell as President and Chief Executive Officer and Director
    On May 6, 2026 (the “Commencement Date”), the Board appointed Michael Edell as the Company’s President and Chief Executive Officer, succeeding Mr. Joel L. Fruendt.
    Mr. Edell, age 62, served as Interim Chief Operating Officer of the Company where he oversaw the Company’s day-to-day operations and execution of its commercial strategy from October 2025 to the Commencement Date. Prior to joining the Company, Mr. Edell founded Westlake Serial Company, LLC in January 2018 and currently serves as a member of its board of directors. Westlake Serial Company, LLC was founded to provide private label consumer package goods in the eco-friendly home cleaning space in addition to providing services to support companies in commercializing existing technologies into consumer-facing products. In April 2025, Mr. Edell also founded Rancher’s Pride, LLC, a wagyu beef-based pet treat company, and currently serves as a member of its board of directors. In March 2008, Mr. Edell founded MaddieBrit Products, LLC (“MaddieBrit”), a consumer package goods products company in the eco-friendly home cleaning space, and served as a member of its board of directors until the company was sold in March 2025. On June 18, 2024, MaddieBrit filed a voluntary petition for relief pursuant to Chapter 11 of Title 11 of the United States Code. In June 2021, Mr. Edell founded Waterleaf Paper Company, a dissolvable wrapping paper company, and served as a member of its board of directors until it was sold in March 2024. Mr. Edell earned his bachelor’s degree from California State University.
    In connection with Mr. Edell’s appointment, the Company and Mr. Edell entered into an offer letter agreement (the “Edell Employment Agreement”). Under the terms of the Edell Employment Agreement, Mr. Edell will receive an annual base salary of $360,000 (the “Base Salary”) and will be eligible to receive an annual incentive bonus with a target opportunity equal to sixty percent (60%) of the Base Salary (each such bonus, an “Annual Bonus”). Any Annual Bonus received with respect to 2026 shall be calculated and paid on a pro-rated basis for his service from April 1, 2026.
    In addition, pursuant to the Edell Employment Agreement, Mr. Edell has been granted an option to purchase 5.0% of the outstanding shares of the Company’s common stock (the “Option”). The Option is scheduled to vest over a three-year period commencing on May 1, 2026, with 1/12th of the shares subject to the Option vesting on the last day of each calendar quarter, subject to Mr. Edell’s continuous service through the applicable vesting date. The Option will not be exercisable unless and until the Company’s stockholders approve an increase in the number of shares reserved for issuance under the SenesTech, Inc. 2018 Equity Incentive Plan.
    In the event of Mr. Edell’s termination by the Company without Cause or his resignation for Good Reason (as such terms are defined in the Edell Employment Agreement), Mr. Edell will be eligible to receive (i) severance benefits equal to six months’ continuation of his then-current base salary, plus one additional month for every completed year of service to the Company after the Commencement Date, up to a maximum of 12 months (the “Severance Period”); (ii) reimbursement of healthcare insurance costs during the Severance Period; (iii) full vesting of the Option; and (iv) a pro-rated Annual Bonus for the year of termination based on actual performance.
    On May 6, 2026, Mr. Edell was also appointed as a member of the Board, and will serve as a Class III director of the Board with a term expiring at the Company’s 2028 annual meeting of stockholders, or until his successor has been elected and qualified or his earlier death, resignation or removal. Subject to the requirements of applicable law (including, without limitation, any rules or regulations of any exchange on which the Company’s common stock is listed, if applicable), the Board or the appropriate committee of the Board is required to nominate Mr. Edell for re-election to the Board at each annual meeting at which he is subject to re-election, as long as he serves as the Company’s Chief Executive Officer. Mr. Edell will not serve on the Board’s Audit Committee, Compensation Committee or Nominating and Corporate Governance Committee, and will receive no additional compensation for his service on the Board.
    Mr. Edell has no family relationship with any of the executive officers or directors of the Company, and he is not a party to any transaction requiring disclosure under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Mr. Edell and any other person pursuant to which he was elected as President and Chief Executive Officer of the Company or as a director. The Company believes that Mr. Edell is a valuable member of the Board because of his experience in the consumer package goods products space together with his role as the Company’s President and Chief Executive Officer.
    Resignation of Joel L. Fruendt
    On May 6, 2026, Mr. Joel L. Fruendt resigned from the Board, and as the Company’s President and Chief Executive Officer.



    Appointment of Matthew K. Szot as Chair of the Board
    On May 6, 2026, in connection with Mr. Edell’s appointment, Ms. Bechtel’s role as Interim Executive Chair concluded. The Board has appointed Matthew K. Szot as the Chair of the Board, succeeding Ms. Bechtel.
    In view of the conclusion of her role as the Company’s Interim Executive Chair, Dr. Bechtel was determined by the Board to be independent within the meaning of Nasdaq listing standards, and the Board also determined that Dr. Bechtel does not have any relationship with the Company that would interfere with the exercise of her independent business judgment.
    Changes to Composition of Board Committees
    In connection with the changes described above, on May 6, 2026, the Board reconstituted the various committees of the Board as follows:
    •Audit Committee:
    ◦Matthew K. Szot (Chairperson)
    ◦Jake S. Leach
    ◦Joshua M. Moss
    •Compensation Committee:
    ◦Jamie Bechtel (Chairperson)
    ◦Matthew K. Szot
    ◦Phil N. Grandinetti, III
    •Nominating and Corporate Governance Committee:
    ◦Jamie Bechtel (Chairperson)
    ◦Matthew K. Szot
    ◦Jake S. Leach
    •Commercialization Committee:
    ◦Phil N. Grandinetti, III (Chairperson)
    ◦Joshua M. Moss
    ◦Lynn Graham
    Supplemental Disclosure Regarding Proposal Three – New Plan Benefits
    The information set forth in the Proxy Statement under the heading “Proposal Three – Approval of an Amendment to the 2018 Equity Incentive Plan – New Plan Benefits” is hereby amended and restated in its entirety as set forth below to reflect the Option granted to Mr. Edell pursuant to the Edell Employment Agreement.
    New Plan Benefits
    The following table sets forth information regarding benefits that may be received under the 2018 Amended Plan by our named executive officers, our non-employee directors and other eligible participants. Except as described below with respect to the Contingent Stock Options approved for our non-employee directors and the Option approved for Mr. Edell in connection with his appointment as the Company’s President and Chief Executive Officer, all awards under the 2018 Amended Plan are discretionary and, accordingly, the benefits or amounts that may be received by any participant are not presently determinable.




    Name and Position
    Dollar Value ($)
    Number of Securities Underlying Options
    Joel L. Fruendt
    $— — 
    Former Chief Executive Officer
    Thomas C. Chesterman
    — — 
    Executive Vice President, Chief Financial Officer, Treasurer and Secretary
    Michael Edell
    — — 
    President and Chief Executive Officer263,288 
    (1)
    Executive Group— 263,288 
    (1)
    Non-Employee Director Group— 420,000 
    (2)
    Non-Executive Officer Employee Group— — 
    ____________
    (1)Pursuant to the terms of the Edell Employment Agreement, Mr. Edell received the Option with respect to 263,288 shares.
    (2)Represents the Contingent Stock Options, with each non-employee director receiving a Contingent Stock Option with respect to 70,000 shares. The Contingent Stock Options are subject to stockholder approval of the 2018 Amended Plan and will be rescinded and deemed not to have been granted if such approval is not obtained.
    Voting Matters
    Please note that any proxy or voting instructions you have submitted for the Annual Meeting is still valid and will be used to vote your shares at the Annual Meeting. If you have already submitted your vote, you do not need to take any further action unless you intend to change or revoke your previous proxy or voting instructions. Information on how to vote your shares and how to change your vote or revoke your proxy or voting instructions is contained in the Proxy Statement. The Company urges stockholders to vote their shares prior to the Annual Meeting by using one of the methods described in the Proxy Statement.

    Get the next $SNES alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNES

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SNES
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SenesTech Expands Distribution of Evolve® Rodent Birth Control™ into Bermuda

    SURPRISE, Ariz., June 4, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced the expansion of its Evolve® Rodent Birth Control™ products into Bermuda through a distribution agreement with Animal and Garden House, marking another step in the Company's growing presence in environmentally sensitive island markets. "Bermuda presents a unique environment for pest management solutions. As a small island with a dense population and close proximity between urban areas and surrounding marine ecosystems, the use of traditional rodenticides has long requi

    6/4/26 8:00:00 AM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Announces Amendment to Equity Incentive Plan Proposal

    PHOENIX, June 3, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES) ("SenesTech" or the "Company"), today announced that its Board of Directors has approved an amendment to the proposed changes to the Company's 2018 Equity Incentive Plan (the "2018 Plan"), which is being presented for stockholder approval at the Company's 2026 Annual Meeting of Stockholders scheduled for June 9, 2026. As previously disclosed in the Company's definitive Proxy Statement filed on April 29, 2026, stockholders are being asked to approve an amendment to the 2018 Plan to increase the number of shares available for future equity awards. Following furth

    6/3/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

    SURPRISE, Ariz., May 19, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026. Company WebcastThe webcast presentation will take place at 2:30 p.m. ET on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at http

    5/19/26 4:30:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $53,486 worth of shares (32,120 units at $1.67) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    5/18/26 8:11:14 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Chief Executive Officer Edell Michael bought $5,013 worth of shares (3,000 units at $1.67) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    5/18/26 4:40:22 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $4,407 worth of shares (3,000 units at $1.47) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    4/30/26 7:19:04 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $53,486 worth of shares (32,120 units at $1.67) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    5/18/26 8:11:14 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Chief Executive Officer Edell Michael bought $5,013 worth of shares (3,000 units at $1.67) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    5/18/26 4:40:22 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $4,407 worth of shares (3,000 units at $1.47) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    4/30/26 7:19:04 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    SEC Filings

    View All

    SEC Form DEFA14A filed by SenesTech Inc.

    DEFA14A - SenesTech, Inc. (0001680378) (Filer)

    6/4/26 4:02:35 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SEC Form DEFA14A filed by SenesTech Inc.

    DEFA14A - SenesTech, Inc. (0001680378) (Filer)

    6/3/26 4:06:13 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SEC Form DEFA14A filed by SenesTech Inc.

    DEFA14A - SenesTech, Inc. (0001680378) (Filer)

    5/27/26 4:01:48 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Leadership Updates

    Live Leadership Updates

    View All

    SenesTech Appoints Michael Edell as President and Chief Executive Officer to Drive Revenue Growth and Scalable Sales Channels

    SURPRISE, Ariz., May 7, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", )), a leader in humane pest control solutions, today announced the appointment of Michael Edell as President and Chief Executive Officer, effective May 6, 2026. The Company also announced Board leadership transition updates to support SenesTech's next phase of commercial growth and operational execution. Mr. Edell brings a proven track record of building and scaling consumer product businesses, with deep expertise in e-commerce, direct-to-consumer execution, and business

    5/7/26 8:30:00 AM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Names Nicole Williams as Chief Revenue Officer

    PHOENIX, Feb. 16, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today reported the appointment of Nicole Williams as Chief Revenue Officer. Ms. Williams was previously Chief Strategy Officer, and this appointment is part of an expansion and restructuring of the sales organization and commercialization efforts. The restructuring of the team comes after yet another quarter and fiscal ye

    2/16/23 9:00:00 AM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G filed by SenesTech Inc.

    SC 13G - SenesTech, Inc. (0001680378) (Subject)

    11/12/24 4:30:48 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Financials

    Live finance-specific insights

    View All

    SenesTech Reports Record Direct-to-Consumer and Subscription Growth Following Strategic E-Commerce Transition

    In-house e-commerce transition and new CEO expected to support scalable recurring revenue growth strategySURPRISE, Ariz., May 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products today announced financial results for the first quarter ended March 31, 2026 and provided an update on the Company's acceleration of revenue under newly appointed Chief Executive Officer, Michael Edell. Q1 2026 Financial HighlightsRevenue increased 2% to $493,

    5/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, May 7, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products, will report financial results for its first quarter 2026, ended March 31, 2026, after the market close on Tuesday, May 12, 2026. The Company has scheduled a conference call that same day, Tuesday, May 12, 2026, at 5:00 pm ET, to review the results. First Quarter

    5/7/26 4:30:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

    SURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025. 2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate re

    3/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials